haloperidol has been researched along with escitalopram in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Brennan, J; Carrick, T; Denny, RA; Feenstra, RW; Graf, R; Grauer, SM; Greenfield, A; Grosanu, C; Kowal, DM; Kruse, CG; Lai, M; Marquis, KL; McCreary, A; McFarlane, GR; Navarra, RL; Neut, Mv; Núñez-García, S; Pausch, MH; Pruthi, F; Reinders, JH; Robichaud, AJ; Rotella, DP; Sullivan, K; Zhang, J | 1 |
| Carrick, T; Feenstra, R; Kowal, DM; Kruse, CG; Lai, M; Marquis, KL; Pausch, MH; Reinders, JH; Robichaud, AJ; Rotella, DP; van der Neut, M; Yan, Y; Zhang, J; Zhou, P | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bucki, A; Głuch-Lutwin, M; Jakubczyk, M; Jamrozik, M; Jastrzębska-Więsek, M; Kołaczkowski, M; Marcinkowska, M; Mierzejewski, P; Partyka, A; Pawłowski, M; Pytka, K; Siwek, A; Śniecikowska, J; Wesołowska, A; Zagórska, A | 1 |
1 review(s) available for haloperidol and escitalopram
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 other study(ies) available for haloperidol and escitalopram
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia.
Topics: Animals; Carbazoles; Disease Models, Animal; Dopamine Agonists; Rats; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT1 Receptor Antagonists | 2009 |
Potent dihydroquinolinone dopamine D2 partial agonist/serotonin reuptake inhibitors for the treatment of schizophrenia.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dopamine Agonists; Quinolones; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Structure-Activity Relationship | 2010 |
Multifunctional 6-fluoro-3-[3-(pyrrolidin-1-yl)propyl]-1,2-benzoxazoles targeting behavioral and psychological symptoms of dementia (BPSD).
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Benzoxazoles; Dementia; Dizocilpine Maleate; Dose-Response Relationship, Drug; Ether-A-Go-Go Potassium Channels; Humans; Male; Mice; Models, Molecular; Molecular Structure; Structure-Activity Relationship | 2020 |